NJ-LABVANTAGE
22.2.2024 13:31:32 CET | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, has made available its semantic search (AILANI), advanced analytics, and LIMS solutions in an integrated, digitally native ecosystem capable of seamlessly supporting R&D laboratory processes. This ecosystem will enable R&D labs to improve efficiency, productivity, decision-making, collaboration, and ultimately time-to-market while reducing operational cost. LabVantage will present its LIMS solutions and integrated ecosystem at Pittcon 2024 (Booth #2133), February 24-28, in San Diego, California.
Digitizing R&D laboratory processes with advanced technologies such as semantic search, analytics, and LIMS marks a significant leap towards efficiency and innovation in the scientific domain. Semantic search capabilities enable the contextualization and searchability of vast amounts of data and documents, utilizing a semantic core and knowledge graph. This technology not only streamlines information retrieval and drastically reduces repetition in experimental runs, but also enhances the decision-making process by providing more relevant and precise data insights. Some LabVantage customers have experienced a 30% reduction in repeated experiments by implementing LabVantage’s semantic search tool, AILANI.
Integrating AI and Business Intelligence into a unified analytics platform, in tandem with LIMS, accelerates analysis and reporting. LabVantage Analytics provides analysis of both structured and unstructured data from diverse sources, integrating data processing, storage, analysis, and visualization in one platform. Its user-friendly self-service features include customizable dashboards and immediate access to LIMS data reports.
“By incorporating advanced technologies like semantic search, AI, and analytics into our LIMS solutions, we're not only enhancing data precision and reducing experimental repetition but also driving significant improvements in collaboration and experiment design. Together, these tools will be instrumental in enabling customers to design better experiments while drastically reducing the total number of experimental runs,” said Alan Marcus, Chief Growth Officer at LabVantage Solutions. “Our goal is to hand back more time to customers for scientific exploration. In fact, we believe these digitally native solutions will expand our ability to serve clients in all supported industries throughout their entire product lifecycle. Your data can now be unified, housed, searched, and analyzed within a single platform from concept to market.”
The implementation of a LIMS automates and manages laboratory workflows, significantly boosting efficiency and consistency in experiment execution. By integrating with search and analytics tools, LabVantage LIMS ensures a seamless flow of information, further elevating laboratory operations, decision-making, and collaboration. Industry statistics underscore the transformative impact of such digitization and automation with laboratories reporting up to a 30-40% increase in productivity.1
LabVantage’s merger with Biomax Informatics has enhanced its analytics and LIMS solutions by integrating AILANI, an advanced semantic search tool. AILANI synergizes semantic modeling, ontologies, linguistics, and AI algorithms to revolutionize query-based research. This tool effectively connects various data sources—internal, external, and proprietary—empowering researchers to swiftly discover valuable insights and hidden patterns. It also simplifies and accelerates decision-making throughout the R&D process by offering easy access to relevant information and its context.
LabVantage Biomax was recognized in the Gartner® Hype Cycle™ for Life Science Discovery Research 2023 as a Sample Vendor for two categories: ‘Semantic Knowledge Graph Tools’ and ‘Analytics Platforms for Research Informatics’.2 Similarly, LabVantage was ranked as a top growth and innovation leader in 2023 by Frost & Sullivan in the firm’s first annual global life sciences LIMS report and radar, highlighting LabVantage's commitment and status as a pivotal player in transforming life science research and analytics.
For more information on LabVantage, its LIMS solutions, and digitally native R&D ecosystem, visit www.labvantage.com or email info@labvantage.com.
References:
- McKinsey & Company. Digitization, Automation, and Online Testing: The Future of Pharma Quality Control. McKinsey & Company Life Sciences.
-
Harwood, R. Gartner® Hype Cycle™ for Life Science Discovery Research, 2023.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222841525/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom